CFO of Alpha Tau Medical Executes Sharp Buy‑Sell Flip, Buying at $2.98 and Selling at $14.00 in Same Day Trade

Insider Activity in Focus: Levy Raphi’s Recent Trades

Levy Raphi, the Chief Financial Officer of Alpha Tau Medical, has been a highly active insider in the past month, oscillating between buying and selling significant blocks of ordinary shares. On 11 August 2026, Raphi purchased 17,730 shares at $2.98 and sold an equal amount at $14.00, resulting in a post‑transaction ownership of 107,910 shares. This dual transaction is a textbook example of “round‑trip” trading that can signal either a tactical portfolio adjustment or a hedge against anticipated price movements. The price differential—buying well below the market price and selling at roughly the current level—suggests that Raphi may have been positioning himself ahead of an upcoming event or simply rebalancing his holdings in light of the company’s recent clinical milestones.

What This Means for Investors

From an investor’s perspective, Raphi’s trading cadence aligns with a pattern of frequent short‑term repositioning. Historically, his trades have spanned from large sells at $12–$13.66 per share to purchases at $2.98–$3.00. The most recent sell on 11 August was executed at the company’s current trading price of $13.66, indicating confidence that the stock is fairly valued at the time. The simultaneous buy at $2.98, however, introduces a potential arbitrage element: if Raphi believes that the stock is temporarily undervalued or that a forthcoming announcement could drive the price higher, the trade could be viewed as a bet on future upside. For the broader market, such insider activity often acts as a signal of management’s expectations about short‑term liquidity or capital structure adjustments, prompting analysts to reassess the company’s valuation metrics.

Levy Raphi: A Profile of Strategic Insider

Raphi’s historical transaction pattern paints a picture of a CFO who is actively involved in the day‑to‑day capital management of Alpha Tau Medical. Over the past two months, he has executed multiple large sales—often in the 15,000–20,000 share range—at prices ranging from $9.47 to $13.66. These moves coincide with periods of market volatility or internal funding needs, suggesting that Raphi may be monetizing equity to support ongoing clinical trials and regulatory submissions. Conversely, his regular purchases at the low $2.98 level, which is markedly below the market price, indicate a willingness to reinvest in the company when it appears undervalued or when he anticipates that forthcoming milestones could unlock value. This duality—selling when the market is high and buying when it is low—highlights a disciplined approach to managing personal wealth while aligning with the company’s long‑term strategy.

Implications for Alpha Tau Medical’s Future

Alpha Tau Medical is in a critical transition phase: clinical milestones have been achieved, yet the company remains unprofitable, as evidenced by its negative P/E ratio and recent quarterly loss. Insider transactions like Raphi’s can serve as a barometer for the management team’s confidence in the business model and its ability to translate clinical success into financial performance. If the company continues to secure regulatory approvals and bring its alpha‑emitter devices to market, the stock could experience a significant upside, potentially vindicating Raphi’s low‑price purchases. Conversely, sustained losses or delays in product commercialization could dampen investor enthusiasm, prompting further insider exits. For stakeholders, the key takeaway is that insider activity is a valuable, though not definitive, signal of the company’s trajectory—and should be weighed alongside fundamental data and market sentiment.

Conclusion

Levy Raphi’s recent round‑trip trade and his broader trading history suggest a CFO who is actively managing his stake in Alpha Tau Medical in response to market conditions and company developments. While the dual purchase‑sell on 11 August may indicate a strategic bet on future upside, it also underscores the CFO’s role in balancing personal wealth and corporate governance. Investors should monitor these insider moves in conjunction with the company’s clinical progress and financial disclosures to gauge the likely impact on Alpha Tau Medical’s stock trajectory.